Creative Medical receives notice of allowance for ImmCelz

Creative Medical (CELZ) Technology Holdings has received a Notice of Allowance from the United States Patent and Trademark Office for a U.S. patent application titled, “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.” Once granted, the patent will be in effect until at least 2040. The patent has broad claims to treat patients who are at risk of developing or who already have heart failure with the Company’s proprietary ImmCelz product. Some patients who experience a heart attack develop post-infarct pathological remodeling, which can lead to reduced heart function and potentially result in heart failure. The total treatable heart failure population in the United States is greater than five million patients. There are also over six million patients who have chronic chest pain despite maximal medical and surgical therapy who may also benefit from the ImmCelz product. The ImmCelz product is delivered to the patient via an ultra-minimally invasive outpatient procedure.